L74 Stock Overview
An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
WuXi XDC Cayman Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.90 |
| 52 Week High | HK$3.84 |
| 52 Week Low | HK$1.45 |
| Beta | 0 |
| 11 Month Change | 2.84% |
| 3 Month Change | 36.79% |
| 1 Year Change | -10.51% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -7.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| L74 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -1.4% | 0.9% | -0.02% |
| 1Y | -10.5% | 2.7% | 8.2% |
Return vs Industry: L74 underperformed the German Life Sciences industry which returned 2% over the past year.
Return vs Market: L74 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| L74 volatility | |
|---|---|
| L74 Average Weekly Movement | 11.1% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: L74's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: L74's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 1,496 | Jimmy Li | wuxixdc.com |
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services.
WuXi XDC Cayman Inc. Fundamentals Summary
| L74 fundamental statistics | |
|---|---|
| Market cap | €3.63b |
| Earnings (TTM) | €78.80m |
| Revenue (TTM) | €370.52m |
46.1x
P/E Ratio9.8x
P/S RatioIs L74 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| L74 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.80b |
| Cost of Revenue | CN¥1.93b |
| Gross Profit | CN¥865.49m |
| Other Expenses | CN¥270.94m |
| Earnings | CN¥594.55m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.50 |
| Gross Margin | 30.96% |
| Net Profit Margin | 21.27% |
| Debt/Equity Ratio | 0.8% |
How did L74 perform over the long term?
See historical performance and comparison